Sisram Medical Ltd. · HKEX:1696
Sisram Medical — FY2020 Earnings Presentation
27 slides from Sisram Medical's earnings presentation, 2021
Slide 1: 2020 Annual Results
Sisram Medical \corporated in Israel with limited liability) Enhancing Quality of Life 2020 Annual Results Sisram Med Stock Code: 1696.HK A A A
Slide 2: Disclaimer
Disclaimer This presentation and the accompanying slides (the “Presentation”) which have been prepared by Sisram Medical Ltd (the “Company”) do not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any
Slide 3: Business Performance Highlights
Business Performance Highlights © 2021 Sisram Medical Ltd. All rights reserved 2020 Results 2021 Outlook & Strategy Appendix
Slide 4: 2020 New Launches
2020 New Launches Sisram, as a leading provider of energy-based devices, launched four new highly innovative products during 2020. Opus Plasma Harmony XL PRO Special Edition • The first fractional plasma skin • Providing a full spectrum of resurfacing platform solutions - over 65 FDA cleared © 2021
Slide 5: Injectable Market Expansion
Injectable Market Expansion Revenue derived from injectables increased 34.2% YoY to US$4.3M in 2020. IBSA Profhilo RZL012 © 2021 Sisram Medical Ltd. All rights reserved • Partnering with IBSA Derma, for the distribution of its • Invested in a start-up company (Tianjin JuveStar) which was products in
Slide 6: Entering into Aesthetic Dentistry & Personal Care Market
Entering into Aesthetic Dentistry & Personal Care Market Aesthetic dentistry and personal care business could see great potential growth and synergies with Alma’s operation. Aesthetic Dentistry Personal Care © 2021 Sisram Medical Ltd. All rights reserved • Aiming to become a holistic digital workflo
Slide 7: Strong Marketing Support
Strong Marketing Support Fully utilizing globalization to overcome challenges during the COVID-19 with our subsidiaries and partners in over 90 countries and jurisdictions Adjusting to the new market dynamics, we have performed the following activities: © 2021 Sisram Medical Ltd. All rights rese
Slide 8: Digitalization
Digitalization Investment in IT Infrastructure: invested US$0.8 million in Information technology infrastructure upgrade in 2020. © 2021 Sisram Medical Ltd. All rights reserved System Upgrade: upgraded Global ERP System upgrade, completed initial implementation of global CRM system and full impl
Slide 9: 2020 Results
Business Performance Highlights © 2021 Sisram Medical Ltd. All rights reserved 2020 Results 2021 Outlook & Strategy Appendix
Slide 10: Key Financial Data 2020
Key Financial Data 2020 55.3% 55.7% (USD million) 53.5% 173.5 162.1 95.9 153.9 90.3 82.3 Gross Profit & Margin 55.3% 55.8% 90.4 Revenue © 2021 Sisram Medical Ltd. All rights reserved 50.4 71.7 39.9 2018 2019 2020 1H20 2H20 2018 2019 2020 1H20 2H20 29.5 Adjusted Net Profit 21.8 21.9 26.9 Net Profit 2
Slide 11: Revenue Breakdown
Revenue Breakdown (USD million) Latin America 5% Non-EBD Services and Middle East 3% Others Europe 5% and Africa 21% Minimally 13% Invasive Product Categories Geographic Areas 12% Beauty © 2021 Sisram Medical Ltd. All rights reserved 9% Asia Pacific Core 27% North 71% America 34% 60 54.4 140 124.4 2
Slide 12: Selling and Distribution
Selling and Distribution (USD million) Distributors, Direct Sales, Distributors, Direct Sales, 72.1, 44.5% 93.5, 53.9% 80.0, 46.1% 90.0, 55.5% 2020 2019 © 2021 Sisram Medical Ltd. All rights reserved % of revenue 26.6% 25.1% Increase in % of direct sales revenue 43.5 43.1 • Revenue derived from dire
Slide 13: Operating Expenses
Operating Expenses (USD million) Administrative Expenses Research & Development Expenses 5.2 5.7 10.5 11.0 © 2021 Sisram Medical Ltd. All rights reserved 10.6 10.2 2019 2020 2019 2020 Amortization Administrative Expenses • Administrative expenses of the Group increased by 0.3% to • Most of the incre
Slide 14: Cash Flow & Turnover
Cash Flow & Turnover (USD million) Operating Activities Investing Activities Financing Activities Cash and Bank Balances 116.5 104.5 107.8 © 2021 Sisram Medical Ltd. All rights reserved 2018 53.7 2019 25.7 2020 21.0 16.2 (4.1) (9.4) (12.2) (17.4) (33.5) Operating activities Days sales outstanding wa
Slide 15: Net Profit Adjustments
Net Profit Adjustments (USD million) 2020 2019 PROFIT FOR THE YEAR 14.7 21.9 Adjusted for: © 2021 Sisram Medical Ltd. All rights reserved Amortization of other intangible assets arising from the Alma acquisitions 4.6 4.6 Amortization of other intangible assets arising from the Nova acquisitions 1.1
Slide 16: 2021 Outlook & Strategy
Business Performance Highlights © 2021 Sisram Medical Ltd. All rights reserved 2020 Results 2021 Outlook & Strategy Appendix
Slide 17: Outlook for 2021
Outlook for 2021 Our efforts throughout 2021 will strategically focus on strategic branding, digitalization, eco-system building and lean innovation • A significant revenue growth of over 40% is expected in the first Management Guidance half of 2021, compared with the revenue achieved in the first h
Slide 18: Outlook for 2021
Outlook for 2021 We plan to focus on the following targets: Reconstruction Business Branch Expansion • Reconstruction of organization • Completing IBSA registration in structure and operation China and introducing additional • The leading player in the global products in injectables © 2021 Sisram Me
Slide 19: Outlook for 2021: Expansion of China Business
Outlook for 2021 Expansion of China Business Synergy with Fosun • Leveraging Fosun’s resources in China to capture a larger market share (for surgical, injectables, beauty and cosmeceuticals segments). © 2021 Sisram Medical Ltd. All rights reserved • Exploring multi strategic collaboration and resou
Slide 20: Sisram Medical Strategic Growth Plan
Sisram Medical Strategic Growth Plan Step 4 Become a leading global player in medical aesthetic market with our vision and mission of “Enhancing Quality of Life” © 2021 Sisram Medical Ltd. All rights reserved Step 3 Extend business branches to build Sisram’s eco-system with B2C and digital approach
Slide 21: Sisram Medical Strategic Growth Plan
Sisram Medical Strategic Growth Plan Sisram Medical is committed to establish a wellness eco-system and become the leading player in the global medical aesthetic market with our vision and mission of “Enhancing Quality of Life”. Alma Energy-based Devices (Lasers, IPL, RF, Ultrasound, Plasma, etc.) ©
Slide 22: Appendix
Business Performance Highlights © 2021 Sisram Medical Ltd. All rights reserved 2020 Results 2021 Outlook & Strategy Appendix
Slide 23: Major EBD Map – Medical Aesthetics
Major EBD Map – Medical Aesthetics © 2021 Sisram Medical Ltd. All rights reserved Soprano Harmony Accent Prime Alma Hybrid • Sisram’s flagship family for the • Over 65 FDA-cleared • Body contouring and skin • Skin rejuvenation and scar treatment of hair removal indications of skin tightening revisio
Slide 24: Major EBD Map – Medical Aesthetics
Major EBD Map – Medical Aesthetics © 2021 Sisram Medical Ltd. All rights reserved ThermoLift DermaClear Legato II Pixel CO2 • Skin tightening and body • deep cleansing, nourishment, • Scars, stretch marks, various • Complete solution for skin contouring and hydration skin imperfections using imperfe
Slide 25: Major EBD Map – Aesthetics Precision
Major EBD Map – Aesthetics Precision © 2021 Sisram Medical Ltd. All rights reserved Alma-Q Pico CLear Sinon II Arion • Pigmented lesions, tattoo • Skin rejuvenation and tattoo • Pigmented lesions and multi- • Hair removal and superficial removal, skin remodeling, removal color tattoos pigmented lesi
Slide 26: Major EBD Map – Surgical
Major EBD Map – Surgical © 2021 Sisram Medical Ltd. All rights reserved FemiLift BeautiFill by LipoLife VascuLife ENTelligence • Minimally-invasive CO2 laser • Liposuction and fat grafting • Varicose veins • Precision CO2 laser solution for various feminine • The first Laser-based fat • 1470nm laser
Slide 27: Thank You !
Sisram Medical (incorporated in Israel with limited liabil Enhancing Quality of Life Thank You ! A A A